13466-38-1

Basic information

• Product Name: 2-Hydroxy-5-bromopyridine
• Synonyms: 2-Hydroxy-5-bromopyridine ,97%;2-Hydroxy-5-broMopyridine, 99% 25GR;2-Hydroxy-5-broMopyridine, 99% 5GR;5-Bromo-2-pyridinol 5-Bromo-2(1H)-pyridinone 5-Bromo-2-pyridone;5-Bromopyridin-2-ol, 5-Bromopyridin-2(1H)-one;2-hydroxy -5-pyridyl broMide;5-BroMo-1H-pyridin-2-one;5-Bromo-2(1H)-pyridone 97%
• CAS NO: 13466-38-1
• Molecular Formula: C₅H₄BrNO
• Molecular Weight: 174
• EINECS: -0
• Product Categories: blocks;Bromides;Pyridines;Pyridine;Alcohols and Derivatives;Heterocycles;Pyridine Series;Halides;Bromopyridines;Halopyridines;C5Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 13466-38-1.mol

Chemical Properties

• Melting Point: 180-183 °C(lit.)
• Boiling Point: 305.9 ºC at 760 mmHg
• Flash Point: 138.8 ºC
• Appearance: Off-white to yellow-brown/Crystalline Powder
• Density: 1.776 g/cm³
• Vapor Pressure: 0.000796mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.96±0.10(Predicted)
• BRN: 108751
• CAS DataBase Reference: 2-Hydroxy-5-bromopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxy-5-bromopyridine(13466-38-1)
• EPA Substance Registry System: 2-Hydroxy-5-bromopyridine(13466-38-1)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-36-22
• Safety Statements: 26-37/39-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 13466-38-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Hydroxy-5-bromopyridine is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, particularly those targeting neurological disorders, as it can be modified to interact with specific receptors in the central nervous system.
Used in Chemical Synthesis:
In the field of organic chemistry, 2-Hydroxy-5-bromopyridine serves as a valuable building block for the synthesis of more complex molecules. Its reactivity with various reagents enables the creation of a wide range of compounds with diverse applications, such as agrochemicals, dyes, and advanced materials.
Used in Research and Development:
Due to its unique chemical properties, 2-Hydroxy-5-bromopyridine is utilized in research and development laboratories for studying various chemical reactions and exploring new synthetic pathways. It can be used to investigate the effects of structural modifications on the reactivity and properties of pyridine-based compounds, contributing to the advancement of chemical knowledge and the discovery of novel applications.
Used in Material Science:
The compound's ability to form crystalline structures makes it a candidate for use in the development of new materials with specific properties, such as optical, electronic, or magnetic characteristics. Researchers can explore its potential in creating advanced materials for various applications, including sensors, energy storage devices, and electronic components.

InChI:InChI=1/C5H4BrNO/c6-4-1-2-5(8)7-3-4/h1-3H,(H,7,8)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 856849-02-0 2-benzyloxy-5-bromo-pyridine-1-oxide 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 51933-78-9 5-bromo-2-(methylsulfanyl)pyridine 
• 142-08-5 2-hydroxypyridin 
• 39856-50-3 5-bromo2-nitropyridine 
• 83664-33-9 2-(benzyloxy)-5-bromopyridine 
• 624-28-2 2,5-dibromopyridine 
• 122256-50-2 1-benzyloxy-5-bromo-2-pyridone 
• 53939-30-3 5-bromo-2-chloropyridine 
• 109-09-1 2-chloropyridine 
• 1493-13-6 trifluorormethanesulfonic acid 
• 504-29-0 2-aminopyridine 

Downstream Products

• 79674-66-1 2-((5-bromopyridin-2-yl)oxy)acetic acid 
• 63785-87-5 5-bromo-1-ethyl-1,2-dihydropyridin-2-one 
• 189954-65-2 3-[(5-bromo-2-pyridinyl)oxy]-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone 
• 381233-75-6 5-bromo-2-hydroxy-3-iodopyridine 
• 882170-27-6 [1-(5-bromo-pyridin-2-yloxymethyl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 83664-33-9 2-(benzyloxy)-5-bromopyridine 
• 1240309-61-8 5-bromo-2-(3-(trifluoromethyl)benzyloxy)pyridine 
• 1193334-67-6 5-bromo-1-cyclopropyl-1,2-dihydropyridin-2-one 
• 1275993-30-0 ethyl 4-[(5-bromopyridin-2-yl)oxy]cyclohexanecarboxylate 
• 1275993-32-2 ethyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yloxy)cyelohexanecarboxylate 
• 1275993-34-4 ethyl 4-(5-amino-2,3'-bipyridin-6'-yloxy)cyclohexanecarboxylate 
• 851087-08-6 5-bromo-1-isopropylpyridine-2(1H)-one 
• 1349151-98-9 1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)pyridine-2(1H)-one 
• 1349731-37-8 5-[5-amino-6-[5-[2-methyl-4-[[[(3S)-tetrahydrofuran-3-yl]amino]methyl]phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-1-isopropylpyridin-2-one 

Relevant articles and documents

Preparation method of 2, 5-dibromopyridine

The invention discloses a preparation method of 2, 5-dibromopyridine, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: reacting 2-hydroxypyridine serving as a raw material with a bromination reagent to obtain 2-hydroxy-5-bromopyridine; and then reacting with a bromination reagent under the action of a Lewis acid catalyst to obtain 2, 5-dibromopyridine. The method is completed in two steps, an isomer obtained in the first step of reaction does not need to be purified, and a product with the purity of 99.5% or above can be obtained through recrystallization once in the last step.

Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia

Accumulating researches have contributed much effect to discover novel chemotherapeutic drug for leukemia with expeditious curative effect, of which bromodomain-containing protein 4 (BRD4) inhibitor is considered as a eutherapeutic drug which has presented efficient cell proliferation suppression effect. In this study, we disclosed a series of phenylisoxazole sulfonamide derivatives as potent BRD4 inhibitors. Especially, compound 58 exhibited robust inhibitory potency toward BRD4-BD1 and BRD4-BD2 with IC50 values of 70 and 140 nM, respectively. In addition, compound 58 significantly suppressed cell proliferation of leukemia cell lines HL-60 and MV4-11 with IC50 values of 1.21 and 0.15 μM. In-depth study of the biological mechanism of compound 58 exerted its tumor suppression effect via down-regulating the level of oncogene c-myc. Moreover, in vivo pharmacokinetics (PK) study was conducted and the results demonstrated better pharmacokinetics features versus (+)-JQ1. In summary, our study discovers that compound 58 represents as a novel BRD4 inhibitor for further investigation in development of leukemia inhibitor with potentiality.

DOCK1-INHIBITING COMPOUND AND USE THEREOF

Provided is a compound that is usable as an active ingredient of an anticancer agent. Preferably provided is a compound that has DOCK1-inhibiting activity and exerts an anticancer effect based on the activity. A compound represented by the following formula (A) or a salt thereof: wherein X represents a carbon atom or a nitrogen atom; Y represents an oxygen atom, a hydroxy group, or a hydrocarbon group; R1 and R2 are different, and each represents a hydrogen atom or a group represented by the following formula (A-1): (wherein R6 represents a pyrrolidino group or a phenyl group, and n2 is 0 or 1) ; R3 represents -CO-R7 (wherein R7 is an alkoxy group, an alkyl group, or an alkylamino group), a 1,3-oxazole group, an alkylhydroxy group, a hydrogen atom, or an oxygen atom; R4 represents a hydrogen atom, an oxygen atom, or a hydrocarbon group in which one or more hydrogen atoms may be replaced by one or more substituents; R5 represents a halogen atom, a halogenated alkyl group, or a halogenated alkylthio group; and n1 is an integer of 0 to 5; and

PYRIDONE DERIVATIVE COMPRISING HETEROATOMIC RING BUTANE SUBSTITUENT, FOR TREATING FIBROSIS AND INFLAMMATORY DISEASES

Disclosed is a compound for treating fibrosis-related diseases, and specifically disclosed are the compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

Identification of an Oxalamide Ligand for Copper-Catalyzed C?O Couplings from a Pharmaceutical Compound Library

A typical pharmaceutical compound library is stocked with molecular diversity and could provide a platform for the discovery of new ligand structures. Herein, we describe the use of this approach in combination with high throughput screening to identify N,N’-bis(thiophene-2-ylmethyl)oxalamide as a ligand that is generally effective for copper-catalyzed C?O cross-couplings to prepare both biarylethers as well as phenols under mild conditions.

HETEROCYCLIC COMPOUNDS WITH MICROBIOCIDAL PROPERTIES

The present disclosure relates to a compound of Formula I, wherein the substituents T, A, W, R2, n, Z, G, Z1 and J are as defined in the description.

2,5-DIBROMOPYRIDINE AND PROCESSES OF PREPARATION

Provided herein is a process for the preparation of 2,5-dibromopyridine.

A highly efficient Suzuki-Miyaura methylation of pyridines leading to the drug pirfenidone and its CD3 version (SD-560)

Efficient introduction of methyl or methyl-d3 into aromatic and heteroaromatic systems still presents a synthetic challenge. In particular, we were in search of a non-cryogenic synthesis of the 5-CD3 version of pirfenidone (4d, also known as Pirespa, Esbriet or Pirfenex), one of the two drugs approved to date for retarding idiopathic pulmonary fibrosis (IPF), a serious, rare and fatal lung disease, with a life expectancy of 3-5 years. The methyl-deuterated version of pirfenidone (4e, also known as SD-560) was designed with the objective of attenuating the rate of drug metabolism, and our goal was to find a green methylation route to avoid the environmental and economic impact of employing alkyllithium at cryogenic temperatures. The examination of several cross-coupling strategies for the introduction of methyl or methyl-d3 into methoxypyridine and pyridone systems culminated in two green and nearly quantitative Suzuki-Miyaura cross-coupling routes in the presence of RuPhos ligand: the first, using commercially available methyl boronic acid or its CD3 analog and the second, employing potassium methyl trifluoroborate or CD3BF3K, the latter obtained by a new route in 88% yield. This led, on a scale of tens of grams, to the synthesis of pirfenidone (4d) and its d3 analog, SD-560 (4e), at 99% isotopic purity.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Asymmetric Homogeneous Hydrogenation of 2-Pyridones

An asymmetric homogeneous hydrogenation of 2(1H)-pyridones has been developed, using a ruthenium complex bearing two chiral N-heterocyclic carbene (NHC) ligands. To the best of our knowledge, the presented reaction is the first example of a homogeneous asymmetric conversion of 2-pyridones into the corresponding enantioenriched 2-piperidones.